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ABSTRACT  
The current work deals with the development of the biopolymer based suppositories for the 
treatment of bacterial vaginosis (BV). BV is characterized with a reduction in the Lactobacillus 
count in the vaginal lumen with the subsequent reduction in pH and growth of the pathogenic 
microorganisms. The mode of treatment of BV by alternative therapies includes either 
restoration of Lactobacillus colonies or restoration of the acidic environment in the vaginal 
lumen. In this study, attempts were made to develop gelatin-based biopolymeric suppositories. 
Further attempts were made to entrap Lactobacillus acidophilus within the suppositories, which 
may help in the release of lactic acid for a prolonged period to restore the acidic pH of the 
vaginal lumen. Microscopic examination of the section showed a homogeneous distribution of 
the viable bacteria within the polymeric matrix indicating its probable use in the treatment of 
BV.  Thereafter, various bioactive agents were also incorporated either in combination of 
Lactobacillus acidophilus or as separate entities. The combination of Lactobacillus acidophilus 
and metronidazole, Lactobacillus acidophilus and lactic acid showed the most promising results. 
 
Keywords: Bacterial vaginosis, gelatin, suppositories, metronidazole, ciprofloxacin, lactobacilli. 
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1.1.Introduction 
The inner genital system in women is a lumen of length 7.5 cm (approx) called vagina. It has 
a pH of ~3.5-4.5. It may be defined as a dynamic ecosystem because of its capability to host a 
diverse microflora (Kale, Trivedi et al. 2005) consisting of anaerobic and aerobic bacterial 
genera and species dominated by the facultative, microaerophilic, anaerobic genus 
Lactobacillus. The activity of Lactobacillus is essential to protect women from genital 
infections and to maintain the natural healthy balance of the vaginal flora (Donati, Di Vico et 
al. 2010). Lactic acid, secreted by Lactobacillus, is responsible in maintaining the acidic pH 
within the vaginal lumen. In addition to the lactic acid, Lactobacillus  also produces hydrogen 
peroxide and antimicrobials (lactocin and bacitracin) which prevent the growth of anaerobic 
pathogenic microorganisms within the lumen (Aroutcheva, Gariti et al. 2001). Any 
compromise with the micro-flora of the vagina may lead to the drastic decrease of the 
Lactobacillus population. Various scientific reports reveal that this disease affects 25% 
(approx) of the women population in India. The women in the urban setup are more prone to 
this disease. According to a recent study, 33% of women population in Delhi were found to 
be affected by this syndrome (Bhalla 2007). Every one out of three women is affected by this 
syndrome at some point of their lives.  This condition may be treated with the local 
application and/or delivery of lactic acid, probiotics (Reid 2001) and antibiotics either singly 
or in various combinations using suppositories (Kale, Trivedi et al. 2005). The therapy 
regimes mainly concentrate on the restoration of the acidic pH or Lactobacillus dominated 
micro-flora. Suppositories often suffers with a disadvantage of migration within the vaginal 
tract after it is inserted resulting in an improper delivery of the active agent. The use of 
mucoadhesive polymers for the development of the suppositories may help in preventing the 
migration of the suppositories within the vaginal tract in addition to the controlled release of 
the bioactive agent (Fontaine and Taylor-Robinson 1990). In the current study, attempts will 
be made to develop suppositories using generally regarded as safe (GRAS) materials. Several 
approaches will be considered to develop gelatin-based suppositories containing 
Lactobacillus, antimicrobials and lactic acid, either alone or in combination. Lactic acid 
being a small molecule will be released almost instantaneously and will lower the pH of the 
vaginal tract which might inhibit the bacterial proliferation in the initial phases (Petrova, 
Petrov et al. 2007) whereas the antimicrobials may inhibit the growth of the pathogenic 
microbes for prolonged period. 
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1.2 Objectives 
 
1. To develop biopolymer-based suppositories containing Lactobacillus, antimicrobials and 
lactic acid, either alone or in combination. 
2. To analyze the efficacy of the suppositories by in vitro techniques. 
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Chapter 2 
 
 
 
 
 
 
 
 
Review of Literature 
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2. Review of literature 
2.1. Vaginal system 
Vagina may be defined as an elastic lumen, which is 7.5 cm (approx) long. The elastic nature 
of the vagina may be attributed to the fibromuscular structure. Vaginal lumen has got three 
layers, viz. an outer layer of areolar tissue, a middle layer of smooth muscle and an inner 
lining of stratified squamous epithelium. The lumen arises from the cervix and extends up to 
vaginal orifice in the perineum. The vagina runs obliquely upwards and backwards at an 
angle of 45
o
 and lies in between the urethra and rectum. Urethra is anteriorly positioned while 
rectum is posteriorly positioned to the vagina. Vagina acts as a connector between the 
external and internal organs of reproduction in women. In normal healthy women, the length 
of the anterior wall is 3 inches (approx) while its posterior wall is 3.5 inches (approx) long. 
The vaginal opening is at the caudal end of the vulva. It is usually partially covered by the 
hymen, a thin membrane of connective tissue. The lubricating fluid of the vagina is secreted 
by the Bartholin’s glands, which is located near the vaginal opening and the cervix. The pH 
of the vagina lies in between 3.5 and 4.5 during the period between puberty and menopause. 
It harbors a number of microorganisms and Lactobacillus is the predominant species. 
Glycogen, an analogue of starch found in animals, is the main source of nutrients for the 
microbial flora residing in the lumen of the vagina. The metabolism of glycogen in the 
vaginal system is mediated by the estrogen hormone via estrogen receptors located in the 
epithelial cells covering the vaginal lumen.  The activity of the estrogen receptors is 
dependent on the ovarian hormonal cycle. The increase in the proliferation of the epithelial 
cells and subsequent increase in the glycogen content during the midcycle stage of the 
menstrual cycle has been attributed to the increase in the estrogen levels (Owen 1975). Due to 
the increased proliferation rate of the epithelial cells, there is an increase in the thickness of 
the epithelial cell layers (Wagner and Ottesen 1982; Patton, Thwin et al. 2000). It has been 
observed that the quantity of the mucus, which lines the vaginal epithelia, increases as the 
estrogen level increases. The increased estrogen level results in the decrease in the viscosity 
of the mucus, which results in a watery discharge. As the menstrual cycle enters into the latter 
half of the follicular phase, the production of the mucus increases by 30 folds (Owen 1975). 
Apart from the change in the epithelial and mucosal layers, the physiology of the vagina is 
also dependent on the menstrual cycle. At the time of menstruation, there is an increase in the 
pH of the vagina to pH=6 at day 2 with the subsequent decrease of the same to pH=4 at day 4 
(Eschenbach, Thwin et al. 2000). Due to the dynamic changes in the environment of the 
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vagina during the menstrual cycle leads to the drastic changes in the ecology of the vaginal 
microflora. In general, it is regarded that Lactobacilli species is the predominant microflora 
responsible for maintaining the pH of the vaginal lumen (Eschenbach, Thwin et al. 2000). A 
recent study on Chinese women has also supported the same (Shi, Chen et al. 2009). But the 
analysis of the DNA of the microflora from the vagina of women indicate that some women 
harbor Atopobium, Megasphaera and Leptotrichia which produces the lactic acid and not the 
lactobacilli species (Zhou, Bent et al. 2004).  
The mucus secreted in the vagina is mainly composed of glycoprotein, mucopolysaccharides 
(i.e. glycogen), electrolytes and a larger fraction of water.  The mucosal layer not only 
provides nutrients to the vaginal microflora but also acts as receptors for them. For example, 
Tamm Horsefall protein (THP) which is present both in the human urine and vaginal region 
promotes adhesion of E. coli to these regions. Though THP is not secreted by the vaginal 
epithelia, their presence in the vagina has been attributed to the regular contact of the external 
vaginal structures with the urine (Hawthorn, Bruce et al. 1991; Otero and Nader-Macías 
2007). Lactobacilli undergoes physicochemical interaction with the vaginal epithelia, which 
helps in the colonization of the lactobacilli and biofilm formation within the mucosal and the 
epithelial layer of the vagina (Busscher and Weerkamp 1987; Otero and Nader-Macías 2007). 
The biofilm consists of the bacterial cell layer(s) and the secretory components from the 
vagina (Bibel, Aly et al. 1987; Otero and Nader-Macías 2007).  
The dynamic nature of the microflora is dependent on the age of the women. As the women 
approaches the age of 45 yrs, the menstrual cycle may either pauses or ceases forever. The 
condition of permanent cessation of the menstrual cycle is regarded as menopause, where 
there is a complete loss of follicullar activity (Farage and Maibach 2006). Quite often, 
menopause is associated with a condition where there is a remarked decrease in the vaginal 
secretions, especially mucus, known as post-menopausal atrophic vulvo-vaginitis. This 
results in the decrease in the lubrication of the vagina causing discomfort during coitus 
(Kamarashev and Vassileva 1997). Also, there is a decrease in the thickness of the epithelial 
layer thereby increasing the susceptibility of the vaginal tissue towards infection and 
associated irritation (Kamarashev and Vassileva 1997; Farage and Maibach 2006). As a result 
of the above conditions, there is a subsequent increase in the vaginal discomfort, dryness, 
burning, itching and dyspareunia (Castelo-Branco, Cancelo et al. 2005). The frictional 
damage of the vaginal epithelia increases due to the exposure of the vaginal tissue to the 
moisture of the urine and is quite a common phenomena. Additionally, there is a subsequent 
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increase in the vaginal pH in the presence of the urinary ammonia which further complicates 
the condition and provides an open invitation for the growth of the pathogenic 
microorganisms (Andersen, Bucher et al. 1994). 
The presence of moisture is a necessity for the of microorganisms on any surface and the 
vaginal system is not an exception (Warren, Bauer et al. 2005). Sweat and transepidermal 
water loss is the major source of hydration of the epithelial cells. Transepidermal water loss 
plays an important role in the hydration of the vulva region (Warren, Bauer et al. 2005). The 
vaginal lumen is kept moist mainly by the vaginal secretion and to a certain extent by the 
urine (Faergemann, Aly et al. 1983). In normal healthy women, there is an increase in the 
dynamic nature of the microflora with an increase in the hydration of the epithelial layer  
(Freinkel and Shen 1969).  This results in the decreased permeability of the mucosal layer for 
the pathogenic organisms. If due to pathophysiological conditions, there is a decrease in the 
moisture content within the vaginal lumen then there is a corresponding decrease in the 
microbial count resulting in the increase in the permeability of the barrier layer (Elias 2007). 
Similarly, it was found that with the increase in the moisture content around the urogenital 
tracts there is a corresponding increase in the microbial activity in and around the interface of 
the urogenital organs and the skin (Farage, Bramante et al. 2007).  
Most microbes have an optimal pH range in which they show an improved activity. Any 
intervention with the pH of the system may result in the growth of other microbes. The same 
phenomenon is also applicable for the vaginal system, which is widely populated with the 
lactobacilli species. The pH of the normal healthy vagina is within 3.5-4.5. The pH is mainly 
maintained by the production of lactic acid by the lactobacilli. Any compromise with the pH 
(due to pathophysiological conditions or physical activities like insertion of contraceptive 
devices and intercourse) may result in the increase of the pH within the vaginal lumen, which 
in turn may result in the lactobacilli population and a subsequent increase in the growth of 
other microbe (Aroutcheva, Gariti et al. 2001). As the lactobacilli count decreases, there is a 
decrease in the production of lactic acid. Lactic acid has a potent anti-microbial property 
which helps in preventing the growth of the pathogenic microbes  (Nieman 1954; Kabara, 
Swieczkowski et al. 1972). Lactobacilli also produce antimicrobial products like bacitracin 
and hydrogen peroxide which further help in the prevention of the proliferation of the 
pathogenic microorganisms (Brook 1999; Reid and Burton 2002). Lactobacilli have the 
capability to excrete the substances, which hinders their multiplication, from the vaginal 
lumen . 2001). Additionally, bacterial interference also plays an 
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important role in checking the growth of the pathogens. Bacterial interference is a phenomena 
by which helpful bacteria utilizes the space, resources and nutrients thereby not allowing the 
pathogens to proliferate (Lina, Boutite et al. 2003). This concept has been successfully used 
for the treatment/ prevention of infections in vaginal region. Similar approaches have been 
used to decrease the infection rate in the nasal mucosa (Lina, Boutite et al. 2003).  
 
The nutrient for the microbes is supplied by the vaginal secretions in addition to the 
secretions from the sweat, apocrine and sebaceous glands. These secretions are composed of 
glycoproteins, polysaccharides, electrolytes, amino acids, nucleic acids and fatty acids 
(Pommerenke and Taylor Jr 1953). The metabolic products secreted by the microbes may 
influence the availability of the nutrients (Cavallo 1987). Fatty acids have shown 
antimicrobial activity (against Streptococcus pyogenes, Staphylococcus aureus and skin 
micrococci) and may help in fine tuning the composition of the microbial flora (Kabara, 
Swieczkowski et al. 1972). They failed to produce substantial activity against gram negative 
bacteria (Ouattara, Simard et al. 1997). Apart from this, some peptides have also shown 
antimicrobial activity against various pathogenic bacteria, fungi, viruses and protozoa 
(Zasloff 2002).  
 
From the above discussion, it is now clear that the interaction amongst the host and the 
microbe may either create a mutually beneficial relationship (e.g. Lactobacillus) or may 
produce a deleterious effect on the host, which will lead to diseased condition and even death 
in severe conditions (e.g. Candida, Gardnerella and/or trichomonas) (Casadevall and Pirofski 
2000). The adhesion of the pathogenic microbes to the epithelial cells is an important factor 
governing the colonization and/or biofilm development. This has been attributed to the 
competition amongst the natural and pathogenic microflora for the receptor sites present in 
the vaginal lumen (Boris, Suarez et al. 1998; Otero and Nader-Macías 2007). Unfortunately, 
there is lack of clear understanding of the molecular basis of adherence of the lactobacilli to 
the epithelial cells of vagina. Some reports suggests that the adherence is mediated by the 
proteins present on the cell surface (Conway and Kjelleberg 1989; Coconnier, Klaenhammer 
et al. 1992; Bernet, Brassart et al. 1993) while some researchers claim that the adherence is 
either mediated by lipoteichoic acid (Sherman and Savage 1986; Granato, Perotti et al. 1999) 
or carbohydrates (Neeser, Granato et al. 2000).  
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2.2 Microflora of the vagina 
Vagina provides a biosynthetic environment which has the capability to sustain a diverse 
ecosystem. The microflora of the vagina can be categorized as transient and resident 
microflora and can easily be distinguished by newer molecular methods. The transient 
microflora are not capable of competing with the resident microflora in establishing a 
permanent residence in the vagina (Lowbury, Lilly et al. 1964). Knowledge about the 
transient and resident microflora of vagina is meager as the interpretation of the available 
data is very difficult. Apart from this, a large number of transient organisms continuously 
migrate from the exogenous source (e.g. anus and urethra).  
 
The composition of the vaginal microflora was first described by Döderlein during the year 
1892. He described the vaginal microflora as gram positive, pleomorphic and asporogenic 
bacteria, which were homogeneously distributed throughout the vaginal lumen and are often 
referred to as bacillus Döderlein (Lepargneur and Rousseau 2002). In a study, where the 
samples were collected from college going students and volunteers throughout the menstrual 
cycle indicates that the vagina is inhabited with the  anaerobic and facultative microflora 
(Bartlett, Onderdonk et al. 1977). Similar results were also obtained from the studies on 
children having age varying from 2 months to 15 yrs (Hammerschlag, Alpert et al. 1978). 
Recent studies have found that lactobacilli are the dominant microflora of the vaginal system. 
The other microbes include Peptococcus species, Bacteroides species, Staphylococcus 
epidermidis, Corynebacterium species, Peptostreptococcus species, and Eubacterium species 
(Bartlett 1977). The lactobacilli species is prevalent throughout the lifespan of women and 
has also been confirmed with molecular identification tools (Stoyancheva, Danova et al. 
2006). The predominance of lactobacilli is lost during various vagina diseases (e.g. bacterial 
vaginitis) as determined both by conventional and molecular identification techniques 
(Stoyancheva, Danova et al. 2006). Amongst the Lactobacillus species, Lactobacillus 
acidophilus was considered to be the dominant microbe present in the vaginal microflora 
(Lachlak, Ageron et al. 1996). With the advent of the use of molecular identification 
techniques, it was found that other species (e.g. Lactobacillus crispatus, Lactobacillus 
gasseri, Lactobacillus iners, and Lactobacillus jenseni) may also dominate the ecosystem in 
the microflora (Vasquez, Jakobsson et al. 2002). The molecular identification techniques have 
the ability to specify the species easily in case of diverse microflora. As described earlier, 
vagina is a dynamic ecosystem and is a complex ecosystem having diversified species of 
Lactobacillus and other microbes. Even though the molecular identification techniques (viz. 
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16s r-RNA analysis, RFLP, heat shock protein) have made the life of the researchers and 
clinician easy, our knowledge is quite limited on the vaginal microflora. The main advantage 
of molecular identification techniques is its fast and efficient methods as compared to the 
conventional culture based methods.  
 
2.3 Bacterial vaginosis (BV) 
BV is a clinical syndrome associated with a group of pathogenic microorganisms rather than 
a specific pathogen. It is a very common manifestation amongst the women population. 
Though the exact causative pathogen has not been figured out, it has been observed that there 
is a corresponding decrease in the population of the lactobacilli species. This results in the 
increase in the pH of the vaginal lumen due to the reduction in the lactic acid production. 
Apart from the lactic acid, the production of lactocin and H2O2 also receives a setback. In 
general, the lactobacilli is replaced with the increased population of pathogenic gram 
negative anaerobic bacteria like E. coli, G. vaginalis, M. hominis and M. curtisii (Hill 1993; 
Hillier 2005). This condition may lead to several complications, which include continuous 
vaginal discharge, high HIV risk, malodor (fishy smell), stomach pain, abortion, infertility, 
preterm birth, chorioamnionitis and urinary tract infection (Hillier, Nugent et al. 1995; 
Afrakhteh and Mahdavi 2007; Darwish, Elnshar et al. 2007). 
 
The microflora diversity of the vagina from the patients of BV was first reported during the 
year 1921 by Schröder. Till recent past, the exact causative microorganism was not known 
and has eluded the scientists for long, newly discovered vaginal microbes during BV were 
often considered as BV causing microbes (Hillier 2005). Currently, BV is characterized by 
Amsel’s criteria (Wang 2000). Amsel’s criteria enumerates four criteria out of which at least 
three criteria has to be met before a woman can be declared as a patient of BV. The criteria 
include 1) watery discharge, 2) pH greater than 4.5, 3) positive amine test, and 4) the 
presence of clue cells (Wang 2000).  
Scientists and researchers have associated BV with the following factors  
1. Vaginal douching by the use of scented soaps or perfumed bubble bath and antiseptics 
during bath (Klebanoff, Nansel et al. 2010) 
2. Women having multiple sex partners or a new sex partner.  
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3. Women with smoking habit are more prone to BV (Ryckman, Simhan et al. 2009). 
4. Use of contraceptives (e.g. spermacides). 
The microflora found in the case of BV do not follow the Koch’s postulates and are resistant 
to that approach (Hillier 2005). Since the pathogenesis of BV is not clear, the management of 
BV is a challenging aspect for the clinicians and throughout the world, it is becoming a very 
common syndrome in women in the reproductive age (Spiegel 1991; Fredricks, Fiedler et al. 
2005). If proper care is not taken in the early phase of BV, then it may lead to secondary 
complications.  In pregnant women, it may either cause preterm delivery or choriamnionitis 
(Hillier, Nugent et al. 1995; Aruna and Jyoti 2007). The low weight of the infants (from BV 
patients) may also be accounted to the preterm birth (Hillier, Nugent et al. 1995).  The risk of 
contracting sexually transmitted diseases (e.g. HIV, like syphilis, gonorrhea and 
trichomoniasis) is higher in BV patients as compared to the healthy individual (Taha, Hoover 
et al. 1998).  
If the patients fulfill the Amsel’s criteria, various diagnostic tests are used for the 
confirmation of the syndrome. The whiff test is the most common test which involves the 
addition of potassium hydroxide solution to the vaginal discharge. The presence of a strong 
fishy smells indicates that the patient is suffering from BV. The microscopic examination of 
the vaginal smear, which is analyzed for the presence of bacteria, white blood cells and clue 
cells, the presence of clue cells indicates BV. The gram staining method,  introduced by 
Dunkelberg in the year 1965, is also a simple method for the diagnosis of BV (Dunkelberg Jr 
1965). The method helps in the confirmation of the presence of gram positive and negative 
bacteria in the vaginal discharge. Recently, a scoring system (on a scale of 10) based on the 
presence of large gram-positive rods, small gram negative or variable rods and small curved 
gram negative to variable rods have been reported. If the score lies in between 7 and 10, then 
the patient is suffering from BV (Joesoef, Schmid et al. 1999). The various modern analytical 
techniques involve the use of polymerase chain reaction and oligonucleotide probes for the 
determination of BV. These methods are fast, reliable and accurate (Fredricks, Fiedler et al. 
2005). Unfortunately, these thechniques are not available in all the labs and the clinician is 
forced to accept the results of the afore-mentioned diagnostic tests.  
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2.4 Treatment of BV 
Many strategies for the treatment of BV are being used by the clinicians all over the world. 
The treatment protocol varies from the use of synthetic drugs to the use of probiotics. In the 
current section, an attempt will be made to explore the different modes of treatment of BV. 
 
2.4.1 Antimicrobials in the treatment of BV 
A lot of antimicrobial agents (e.g. ampicillin, penicillin, and metronidazole) have been used 
in the treatment of bacterial vaginitis (Spiegel 1991).  Metronidazole have evolved as a drug 
of choice for the treatment of BV and is the widely prescribed drug. It is a nitroimidazole 
derivative, having activity against anaerobic microbes and protozoans. It has been 
administered either orally or locally. Tablets of metronidazole are easily available for oral 
administration. Formulations for the local administration of the drug include gels and 
suppositories (Adegboye and Itiola ; Decena, Co et al. 2006; Sobel, Ferris et al. 2006; 
Mitchell, Hitti et al. 2009).  Metronidazole and tinidazole (a chemical analogue of 
metronidazole) are preferred for the treatment of BV as against ampicillin. Tinidazole has a 
better pharmacokinetics and longer half-life than metronidazole and its recommendation for 
the treatment of BV is on the rise (Dickey, Nailor et al. 2009). The use of ampicillin is 
avoided due to the emergence of ampicillin resistant bacteria in patients with BV. It also 
inhibits the growth of lactobacilli (Spiegel 1991). The acceptance of suppositories is lower 
than the oral administration of the drug as they might cause irritation (Adegboye and Itiola). 
The insertion of suppositories into the vagina also creates problem with the patient’s 
compliance and is worse in working women. In a recent study, it has been reported that the 
mode of administration of metronidazole, either orally or locally, do not have a significant 
difference in the eradication of the pathogenic bacteria (Mitchell, Hitti et al. 2009). The 
release of the metronidazole from the suppositories is dependent on the composition of the 
formulation. The release rate may be tailored by the incorporation of adjuvant.  Amongst the 
metronidazole gels and lactic acid gels, for local application, lactic acid gels have been found 
to be more efficient and safer. The gel formulation containing a combination of both lactic 
acid and metronidazole has shown superior ability to recolonize the vaginal lumen with 
lactobacilli. The recurrence of BV is less common in patients treated with lactic acid gel 
when compared with patients treated with metronidazole gels (Decena, Co et al. 2006). This 
may be attributed to the hindrance and/ or inhibition in the growth of the lactobacilli when 
metronidazole is used for the treatment and depends on the concentration of the lactobacilli  
(Simoes, Aroutcheva et al. 2001). Studies on the treatment of the BV have also been done 
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with tinidazole, clindamycin, polystyrene sulfonate, and cellulose sulfate, policarbophil-
carbopol acidic vaginal gel (Simoes, Citron et al. 2002; Nyirjesy, McIntosh et al. 2006; Otero 
and Nader-Macías 2007; Dickey, Nailor et al. 2009). Reports on clindamycin have suggested 
that it can be used in the treatment of BV and may be administered either orally or locally 
(McGregor, French et al. 1994). Intravaginal deliveries of clindamycin and metronidazole for 
the treatment of BV have shown that there was an improvement in the clinical symptoms of 
the patients within 21 to 30 days of the starting of the treatment. Unfortunately, the vagina 
was not recolonized with lactobacilli within the stated period (Sobel, Ferris et al. 2006). The 
use of formulation consisting policarbophil-carbopol and lactic acid-chitosan mucoadhesive 
vaginal gels have also been reported (Zhou, Bent et al. 2004; Bonferoni, Giunchedi et al. 
2006). The policarbophil-carbopol gels have been found to be safe (Zhou, Bent et al. 2004). 
Similarly chitosan based lactic acid delivery gels have also been found to be a safe 
(Bonferoni, Giunchedi et al. 2006).  
Unfortunately, there is an increased number of reoccurrence of BV when the synthetic 
antimicrobials are used and may be attributed to the development of antimicrobial resistance 
mechanism within the microbes  (Beigi, Austin et al. 2004). Hence, the researchers and 
clinicians are looking for alternative methods for the treatment of BV. 
 
2.4.2 Probiotics in the treatment of BV 
The importance of probiotics in maintaining a normal health in human and animals was 
described by Dr. R. Fuller during the year 1989 (Ouwehand, Salminen et al. 2002). It has 
recently been described as “Live microorganisms which when administered in adequate 
amounts confer a health benefit on the host” by the WHO (Reid, Jass et al. 2003). The 
lactobacilli, present in curd and different milk products, have also been categorized under 
probiotics. From the discussions in the previous sections, it is quite clear now that lactobacilli 
plays an important role in the inhibition of growth, adhesion and spread of pathogenic 
microbes. This has been accounted to its ability to form biofilms over the mucosal layer of 
the vagina and thereby compete for the nutrients and recpetors with the pathogenic microbes 
(Lepargneur and Rousseau 2002). In addition to this, they secrete lactic acid, H2O2, 
bacteriocins and biosurfactants which have good antimicrobial property. Apart from the 
antimicrobial property of lactic acid, they help in maintaining the pH of vagina within 3.5-4.5 
thereby not allowing a conducive  environment for the growth of the pathogenic microbes 
(Aroutcheva, Gariti et al. 2001). Lactobacillus fermentum, Lactobacillus casai, Lactobacillus 
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acidophilus and Lactobacillus iners are some of the species which have been found in vagina 
(Burton, Cadieux et al. 2003). 
2.4.2.1 Selection criteria for probiotic for the treatment of BV 
The absence of Lactobacillus from the vagina is the specific feature of BV (Hillier 1993). 
The major question in the treatment of BV with the use of lactobacilli as probiotics is whether 
it can cure BV and can inhibit the reoccurrences. Also, which species of lactobacilli can 
effectively inhibit the pathogens (e.g. Escherichia coli and Gardnerella vaginalis) and at the 
same time allow recolonization of the (Reid and Bocking 2003). The exact species of 
Lactobacillus for the treatment of BV may be selected based on the antipathogenic activity of 
the species. The consideration of following factors should also be taken into consideration 
before selecting the Lactobacillus species(Mclean and Rosenstein 2000): 
1) Production of lactic acid (Juarez Tomas, Ocana et al. 2003),  
2) Production of H2O2 (Eschenbach, Davick et al. 1989),  
3) Adhesion of the species to the epithelial layer (Boris, Suarez et al. 1998)  
4) Production of antimicrobials (Hamdan and Mikolajcik 1974; Abee, Klaenhammer et 
al. 1994). 
 
2.4.2.2 Probiotic treatments available for BV 
 
Sour milk and fermented milk were conventionally used for various health benefits. Elie 
Metchnikoff proposed the use of lactic acid producing bacteria as probiotic, with scientific 
reasons, during the year 1907 (Anukam, PhD et al. 2008). He was the first person to propose 
the use of Lactobacillus in the restoration of gastrointestinal flora (Sieber and Dietz 1998; 
Anukam, PhD et al. 2008). Various commercially available Lactobacillus-based products for 
the treatment of BV include yoghurt, acidophilus milk and available Lactobacillus powder 
and tablets(Hughes and Hillier 1990). 
Two types of treatment methodologies are available for the treatment of BV using probiotics. 
The first one includes the oral administration of the Lactobacillus whereas the second method 
includes the local administration of the same in the vagina of the patient. The probiotics, 
when orally administered, have the natural ability to migrate to the vaginal region from the 
intestine via perineal and vulval skin. Studies using Lactobacillus rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 have confirmed the phenomena (Reid, Bruce et al. 2001; 
Anukam, Osazuwa et al. 2006). The treatment of pregnant women,with symptoms with BV,  
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was carried out with yoghurt containing Lactobacillus acidophilus. Vaginal douching of the 
patients were done with the yoghurt, continuously for a week and was repeated after every 1 
week’s interval. The treatment helped in improving the conditions of the patients (Tasdemir, 
Tasdemir et al. 1996). Similar results were observed when yoghurt was locally applied in the 
vaginal lumen. At the cessation of the study, the vaginal pH was within the normal range and 
the presence of Lactobacillus within the lumen was also observed (Neri, Sabah et al. 1993). 
This kind of treatment may result in the decrease of the watery vaginal apart from its bacterial 
recolonization effects (Chimura, Funayama et al. 1995). In a recent study, two groups of 
women were treated with Lactobacillus- based products. The first group was treated with L. 
acidophilus suppositories whereas the second group was treated received a combination of L. 
acidophilus suppositories and oral dose of L. paracasai for a period of 3 months. Both the 
groups showed an increase in the colonies of Lactobacillus with a concurrent restoration of 
the pH. In addition to this, the group which received combination therapy, showed an 
increase in the restoration of the intestinal microflora (Delia, Morgante et al. 2006). 
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3. Method and Materials 
3.1 Materials 
Lactobacillus MRS (de Man, Rogosa and Sharpe) agar, Lactobacillus MRS broth and 
gelatine (extra pure) were procured from Hi-Media, Mumbai, India. Beef Extract, peptone, 
sodium chloride, nutrient broth, crystal voilet solution, glutaraldehyde (25%, analytical 
grade) and hydrochloric acid (HCl, 35%) were purchased from Merck Mumbai, India. 
Gram’s iodine and safranine solution were purchsed from Nova biotech, Kolkata, India and 
SD’S chemical, Mumbai, India, respectively. Becelac Forte containing Lactobacillus 
acidophilus was purchased from Dr. Reddy lab purchased. The composition of Becelac Forte 
is biotin (100 µg), calcium pantothenate (50 mg), cyanocobalamin (15 µg), folic acid (1.5 
mg), Lactobacillus acidophilus (2000 lacs) and niacinamide (100 mg). The bacterial strains 
of E. coli (NCIM strain no.-5051) and Bacillus subtilis was procured from NCIM Pune. 
Ciprofloxacin was purchased from fluka biochemika (Sigma-aldrich) and metronidazole was 
received as gift from Aarti drugs, Mumbai, India. Metrozyl® dental gel, Lekar Pharma Ltd. 
Khatraj, India, was purchased from local market. Lactic acid was procured from loba chemie. 
Rectified spirit and pure ethanol analytical grade were purchased from Trimurty Chemical 
Industries, Cuttack, India and Changshu Yangyuan chemical, China respectively. Fresh goat 
intestine were procured from the local butcher shop. Unionized mili-Q water used 
throughtout the study. 
3.2 Methods 
3.2.1 Preparation of MRS broth and agar  
MRS broth was prepared by mixing 55.15 g of MRS Lactobacillus broth powder into 1 L of 
mili-Q water folowed by autoclaving at 121 
o
C and 15 psi pressure for 15 min. Autoclaving 
solved two purposes. It enhanced the dissolution of the broth media and simultaneously 
sterilized the broth.  
MRS agar was prepared by the addition of the 66.33 g of MRS agar powder into 1 L of mili-
Q water followed by autoclaving at 121 
o
C and 15 psi pressure for 15 min. Autoclaved MRS 
agar solution were immediately poured into the petriplates and allowed to solidify.  
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 3.2.2 Preparation of nutrient broth and agar  
Nutrient broth was prepared by dissolving 10 g of beef extract, 10 g of peptone and 5 g of 
sodium chloride into 1 L of mili-Q water. The above solution was subsequently autoclaved. 
Nutrient agar media was prepared by mixing 28 g of nutrient agar powder in 1 L of mili- Q 
water and was subsequently autoclaved. The hot media solution was immediately poured into 
sterile petriplates and was allowed to solidify. 
3.2.3 Culturing of Lactobacillus  
Lactobacillus cultures were obtained from the Becelac forte® capsule. The culture was 
prepared by inoculating the freshly prepared MRS broth with the contents of the Becelac 
forte® capsule. Thereafter, the inoculated broth was incubated at 35 
o
C for 36 hours in an 
orbital incubator shaker. Serial dilution method was used to obtain a single colony culture 
from the broth culture. The broth was diluted 10
-6 
fold (illustrated in figure 1) and was mixed 
with freshly prepared warm MRS lactobacillus agar solution in a petriplate and left to solidify 
under laminar hood. Thereafter the plate was incubated for 18 h at 35 
o
C in an orbital shaker 
incubator.   
        1ml MRS broth   sample 
 
                                                                                    
Figure 1: Method of serial dilution 
Streak plate method was used to prepare a culture from the single colony obtained from the 
spread culture. After streaking, the petriplate was incubated at 35 
o
C for 18 h. After the 
incubation for 18 h, L. acidophillus culture was stored at 4 
o
C. The culture can be stored up to 
2 weeks under the given condition. The culture can be maintained by repeated inoculation at 
regular intervals of time, which should be less than 2 weeks. To be on the safer side, the 
cultures were re-inoculated every week. The gram staining of the L. acidophillus culture were 
1 ml (10-6      
dilution) 
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done using standard gram staining technique(Xu 1997) and the microscopic pictures were 
obtained from the microscope (Hund Wetzlar, Model # H600, Germany) to characterize the 
bacterium. 
 
3.2.4 Preparation of the suppositories  
Twenty per-cent (w/v) gelatin solution (GS) was prepared by dissolving 8 g of gelatin in 30 
ml of warm water and the final volume was adjusted to 40 ml. To the above solution, a 
mixture of 350 µl of glutaraldehyde and 250 µl of hydrochloric acid was added with 
continuous stirring and were subsequently poured into 15 ml falcon tube (used as mold). The 
suppositories were isolated after 10 min, which allowed the crosslinking of gelatin. The 
prepared suppositories were measured and weighted for physical characterization. Pictures 
were taken with the help of a Sony 10 MPixel camera.  
Lactobacillus loaded suppositories were prepared by suspending 40 mg of bacteria into the 
warm gelatin solution, having 8 g of gelatine in 30 ml water. The rest of the procedure was 
same as above.  The biopolymeric suppositories were incubated in MRS broth to analyse the 
viability of the entrapped bacteria. The MRS broth containing Lactoacillus acidophillus 
based suppositories were incubated period of 18 h. After 18 h of incubation, the suppositories 
were harvested and a thin section of the same was cut. Gram staining was done for the sliced 
section and was observed under microscope.  
3.2.5 Antimicrobial study 
Samples loaded with ciprofloxacin, metronidazole, Lactobacillus acidophillus, lactic acid, 
lactic acid + Lactobacillus acidophilus, metronidazole + Lactobacillus acidophilus, and 
metronidazole + lactic acid + Lactobacillus acidophillus were developed to study the 
antimicrobial activity of the suppositories. Blank samples served as control. Hydrochloric 
acid was not added to the samples containing lactic acid. The compositions of the samples 
have been tabulated in Table 1.  The method of preparation is similar to the development of 
Lactobacilli-loaded suppositories. The only exception being the crosslinking reaction was 
carried out in petriplates instead of falcon tubes.  
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Table 1- Composition of the suppositories prepared 
 
 
sample 
Components 
Gelatin 
solution 
(20% w/v; 
ml) 
 
Ciprofloxacin 
(g/ml) 
Metronidazole 
(g/ml) 
Lactobacillus 
acidophilus 
(g/ml) 
Lactic acid 
(g/ml) 
b-cGG 40   - - - 
CF-cGG 40 0.005 - - - 
MZ-cGG 40 - 0.005 - - 
LA-cGG 40 - - - 0.036 
LB-cGG 40 - - 0.001 - 
MZLB-cGG 40 - 0.005 0.001  
LALB-cGG 40 - - 0.001 0.036 
MZLALB-
cGG 
40  0.005 0.001 0.036 
 
Circular discs of 12 mm were cut using a borer from the bioactive agent loaded samples and 
blanks. These discs were put into the wells, having a diameter of 13 mm, prepared in the 
nutrient agar plates. 500 µl of E. coli suspension, from the culture broth, was added on the 
nutrient agar culture plate and was spread over the surface of the plate with the help of L-
shaped spreader. The plates were subsequently incubated at 35 
o
C for 12 h. The comparative 
antimicrobial efficacy of the antimicrobials was studied on the basis of the zone of inhibition. 
The study was continued for 48 h for the blank samples so as to check the biodegradability of 
the crosslinked gelatine gel. Pictures were taken at 12, 24 and 48 h of incubation.   
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The effect of the bioactive active agents on L. acidophillus was studied in a similar manner as 
described above, where E. coli was replaced with 500 µl of Lactobacillus culture. The 
samples were incubated for 36 h and observations were made after 18 and 36 h.   
A comparative study was done amongst the MZ-cGG and Metrozyl® with E. Coli as the 
challenging microorganism. The concentration of metronidazole used for the development of 
MZ-cGG in this study was 10 mg/ml and was named as MZ-cGG_1. This was done to have 
same amount of drug concentration in both the formulations. 0.7 g of both the samples was 
used and the study was continued for a period of 12 h. At the end of the study, zone of 
inhibition for E. coli was measured. 
3.2.6 In vitro drug release studies 
Accurately weighed 6 g of the MZ-cGG were dipped into a beaker containing 50 ml of water. 
For the first hour, the MZ-cGG were taken out from the beaker and were put into a beaker 
containing fresh 50 ml of water at every 10 min interval. After 1 h, the changeover was done 
at an interval of 30 min. After 2 h, the changeover was done at an interval of 60 min. 2 ml of 
the media containing the drug was collected, at the above-mentioned intervals, in a test-tube 
and the rest was discarded.  The experiment was carried out for a period of 8 h. The amount 
of metronidazole released was measured at λmax of 255 nm using UV-visible 
spectrophotometer (Shimadzu UV 1601 r). 
 
3.2.7 Mucoadheshion testing by In vitro wash off method 
The mucoadhesive properties of b-cGG were evaluated by in vitro wash off method. A 
freshly excised piece of goat intestine mucosa (2.5 cm × 2.5 cm) was mounted on a glass 
slide (7.5 cm × 2.5 cm) with the help of Fevi Kwik®. The b-cGG sample (2.5 cm × 2 cm) 
was placed over the intestine mucosa and weight of 2 gm was applied over it for 5 minutes. 
Then the prepared specimen was transferred to the beaker and placed on an angle of 60 
o
C 
from the surface beneath. The beaker was filled up by 1 L mili-Q water and was kept under 
stirring at 150 rpm using an overhead stirrer. The test was carried out until the gel was 
removed from the mucosal surface. 
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4. Results and discussion 
4.1 L. acidophillus culture  
L. acidophillus was isolated from Becelac forte® capsules by serial dilution method using 
MRS broth. The isolated bacteria were cultured at 35 
o
C and were subsequently maintained at 
4 
o
C on MRS agar media (Nighswonger, Brashears et al. 1996). Figure 2a shows the colonies 
obtained by serial dilution method while figure 2b shows the culture obtained by streaking 
the spread plate colonies for maintenance. MRS broth and agar helps in selective growth of 
lactobacilli species due to the presence of sodium acetate and salt of manganese and 
magnesium(Hartemink, Domenech et al. 1997).   
 
 
                                               
 
 
 
(a)                                                                              (b) 
Figure 2. (a) Lactobacillus acidophilus culture plate obtained after serial dilution (b) 
Lactobacillus acidophilus culture obtained by streak plate method for a single colony of 
(a). 
The isolated bacteria were morphologically characterized by gram staining. The micrographs 
of the gram stained bacteria, isolated from the capsules have been shown in figure 3. The 
results indicate the presence of rod shaped purple colored gram positive bacteria 
(characteristics of lactobacilli species) and absence of any other contaminants.  
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Figure 3. Micrograph of gram stained L. acidophillus 
4.2 Preparation of suppositories  
The developed gelatin-based b-cGG suppositories have been shown in Figure 4a and 4b.  
The lactobacilli loaded suppositories were prepared in a similar manner. For checking the 
viability, the lactobacilli loaded suppositories were incubated overnight in MRS media. The 
MRS media was turbid after the incubation and the gram staining of the thin slice of the 
suppositories confirmed the presence of live L. acidophilus (Figure 4c). The result indicates 
that the bacteria were able to overcome the glutaraldehyde treatment shock and proliferated 
with ease.  
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                                (a)                                                                                           (b) 
 
 
 
 
                        
 
                                                                                 (c) 
Figure 4. (a) & (b) Gelatin-based suppository; (c) Micrograph of the sliced lactobacilli 
loaded suppository, after incubation. 
4.3 Antimicrobial study against E. coli  
E. coli is one of the main causative organisms for BV (Reid and Bocking 2003). Hence, it 
was used as a model microorganism to test the efficiency of the developed biopolymeric 
suppositories loaded with antimicrobials, lactic acid, L. acidophillus and combinations of all 
three. The antimicrobials used in the study include ciprofloxacin and metronidazole. 
Ciprofloxacin is a broad-spectrum antibiotic with activities against both gram +ve and gram –
ve bacteria but its activity is higher against gram –ve bacteria. Most of the microbes 
responsible for BV are gram –ve bacteria. Metronidazole is the drug of choice for the 
treatment of bacterial vaginitis and hence was used in the study. Many metronidazole based 
tablets and gels are available in the market for the treatment of the BV. Lactic acid containing 
gels have also been used in the treatment of BV. L. acidophillus secretes lactic acid, H2O2 and 
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antimicrobials (viz. lactocin and bacitricin), which allows them to combat the pathogenic 
bacteria. The weight and size of the all samples were 0.7 g and 12 mm, respectively. The 
results of the test are shown in figure 5 and have been tabulated in table 2.  
 
Figure 5. Antimicrobial activity against E. coli (a) MZ-cGG suppository (b) CF-cGG 
suppository (c) LA-cGG suppository (d) b-cGG suppository, control (e) MZLB-cGG 
suppository (f) LB-cGG suppository (g) LALB-cGG suppository (f) MZLALB-cGG 
suppository 
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Table 2. Antimicrobial activity against E. coli 
Samples Zone of inhibition 
(mm) 
b-cGG 00 ± 0 
MZ-cGG 35 ± 2 
CF-cGG 50 ± 5 
LA-cGG 25 ± 7 
MZLB-cGG 25 ± 5 
LB-cGG 20 ± 4
 
MZLALB-cGG 25 ± 4 
LALB-cGG 22 ± 3 
 
The inhibition zones of the E. coli culture in the presence of the suppositories were in the 
following order: ciprofloxacin > metronidazole > lactic acid, metronidazole + Lactobacillus, 
metronidazole + lactic acid + Lactobacillus > lactic acid + Lactobacillus > Lactobacillus.  
Ciprofloxacin, metronidazole and lactic acid containing suppositories showed a clear zone of 
inhibition around the wells for a period of 12 h (figure 5). These bioactive agents were able 
to inhibit the growth of E. coli for a prolonged period indicating the sustained action of the 
same and probable use in controlling the growth of E. coli during the treatment of BV. 
The LB-cGG samples have shown a distinct circular zone adjacent to the wells containing the 
samples (figure 6). This zone was followed by a continuous culture of E. coli. The cells from 
the adjacent layer of the wells were collected and were subjected to gram staining.  The 
results showed the presence of purple colored rod shape gram-positive bacteria and not E. 
coli. This can only happen when the metabolic products of lactobacilli (viz. lactic acid, H2O2, 
lactocin and bacitricin) have inhibited the growth of E. coli, which have allowed the 
lactobacilli to migrate out from the LB-cGG samples and colonize the vicinity of the wells. 
This indicates that Lactobacillus not only has the ability to inhibit the growth of E. coli, it can 
even proliferate in the presence of E. coli. The result explains the conventional use of 
lactobacilli based products (e.g. gels and yoghurt) for the treatment of BV (Neri, Sabah et al. 
1993) 
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The MZLB-cGG and LALB-cGG samples have shown several colonies in the inhibition zone 
(figure 6). The morphologies of the colonies were different from the morphology of E. coli. 
Gram staining of the colonies showed purple colored rod shape gram-positive bacteria 
indicating that the lactobacilli from the suppository migrated out of the suppository. The 
finding is quite interesting and may allow the simultaneous delivery of metronidazole and 
lactobacilli using a same delivery system. Reported literatures suggest that BV treated with 
metronidazole, both by oral and local administration, do not show any colonization of 
lactobacilli within the vaginal lumen, though there is an improvement in the conditions of the 
BV patients (Anukam, Osazuwa et al. 2006). Until the vagina is rehabilitated with 
Lactobacillus, there are every chances of reoccurrence of the condition. Hence, the use of 
MZLB-cGG delivery system may allow recolonization of the vagina with Lactobacillus apart 
from the eradication of the pathogenic microorganisms. Similar results were also obtained 
with LALB-cGG samples indicating that LALB-cGG samples have the ability to effectively 
inhibit the growth of E. coli and may help in reducing the use of metronidazole for the 
treatment of BV. Though MZLB-cGG have shown slightly better inhibition zone as 
compared to LALB-cGG, the use of LALB-cGG may be preferred as there are increased 
chances of the development of bioactive agent resistant pathogenic microbes against 
metronidazole as against lactic acid or Lactobacillus (Beigi, Austin et al. 2004). 
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                                    (a)  (A) LB-cGG sample (B) MZLB-cGG sample 
 
                                                        (b)  LALB-cGG sample 
Figure 6. Antimicrobial activity of Lactobacillus acidophillus based products against E. 
coli culture. 
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The samples of b-cGG (control) did not show any zone of inhibition indicating that the blank 
suppository did not show any antimicrobial activity (figure 7). The results confirm that 
glutaraldehyde did not exert any toxic response and the sample may be regarded as 
biocompatible. It was also found that E. coli brought a change in the physical property of the 
b-cGG samples, which became liquid at the end of 48 h indicating its complete degradation. 
This change in the physical property can be attributed to the corresponding change in the 
chemical properties of the samples. The physical property of the b-cGG changed during the 
course of the study indicating that the metabolites produced by the E. coli was able to bring 
some chemical change in the b-cGG network. The results indicate that the gelatin-based 
suppositories may be used for the treatment of BV. 
 
 
 
 
 
 
                           (a)                                                                        (b) 
 
 
 
 
 
 
                                                                        (c)  
Figure 7. (a), (b) and (c) showing the biodegradability of control sample by E.coli, (a) 
after 12 hours, (b) after 24 hours and (c) after 48 hours 
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Figure 8. Comparative antimicrobial study on E. coli. (A) MZ-cGG_1 and (B) 
Metrozyl® 
An antimicrobial comparative study was carried against E. coli so as to judge the activity of 
the prepared metronidazole loaded suppository as against metrozyl®, a marketed 
metronidazole formulation. Metrozyl® consists of metronidazole at a concentration of 10 mg/ 
gm of gel. To carry out the comparative study, gelatin based samples were prepared which 
contained metronidazole at the same concentration and were named as MZ-cGG_1. (The 
experimental results showed that MZ-cGG_1 created greater zone of inhibition as against 
metrozyl® (figure 8). This indicated that MZ-cGG_1 is more effective compared to 
metrozyl®.  
 
4.4 Antimicrobial study against L. acidophillus 
The effect of suppositories on lactobacilli were also analyzed (figure 9, table 3). The results 
showed that b-cGG samples do not have any detrimental effect on lactobacilli and may be 
used for the development of biopolymeric suppositories. This result is also a support for the 
previous results in which lactobacilli was entrapped within the crosslinked gelatin samples 
and did not show any detrimental effect on lactobacilli. The zone of inhibition in the presence 
of MZ-cGG sample was found to be 25 ± 3 mm at the end of 18 h. On further incubation, the 
zone of inhibition was found to be 14 ± 4 mm at the end of 36 h. This might be attributed to 
the improved resistance of the Lactobacillus to metronidazole. To confirm the same, the old 
samples of MZ-cGG were replaced with fresh samples and were further incubated for 12 h. It 
was found that Lactobacillus was able to grow towards the sample and finally showed no 
zone of inhibition. This confirmed that the Lactobacillus became resistant to metronidazole 
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and were able to grow even in the presence of metronidazole, when administered along with 
the antimicrobial. CF-cGG samples showed an inhibition zone of 55 mm, which did not 
recover from the ciprofloxacin shock indicating that the ciprofloxacin samples cannot be used 
for the treatment of BV, where the restoration of Lactobacillus colonies within the vagina is a 
must.  
 
Figure 9. Antimicrobial activity against Lactobacillus acidophilus (a) b-cGG sample 
(control) (b) MZ-cGG samples (18 h incubation) (c) CF-cGG samples (18 h 
incubation)  (d) MZ-cGG samples (36 h incubation) 
Table 3. Antimicrobial activity against L. acidophillus 
Sample Zone of inhibition: 18 h 
incubation 
(mm) 
Zone of inhibition: 36 h 
incubation 
(mm) 
b-cGG 0 0 
CF-cGG 55 ± 8 55 ± 6 
MZ-cGG 25 ± 3 14 ± 4 
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4.5 Drug release study 
The release profile of metronidazole from MZ-cGG is shown  in figure 10. The study was 
carried out for a period of 8 h. The results indicate an initial burst release of metronidazole up 
to 1 h. Thereafter, the rate of release of the drug became slower. At the end of 8 h, it was 
found that only 60 % drug was released from the MZ-cGG sample indicating a sustained 
release of metronidazole from the crosslinked gelatin matrix.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Release profile of metronidazole from MZ-cGG sample. 
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Figure 11. Release kinetics of metronidazole from MZ-cGG sample. 
 
The release kinetics of the metronidazole from the gelatin matrix showed Higuchian kinetics 
indicating diffusion controlled release of metronidazole (figure 11). This model of release 
kinetics is followed by the matrix type delivery system in which the drug is homogeneously 
distributed throughout the polymer matrix of the delivery system. When the delivery matrix is 
bathed in the dissolution solution, the drug present in the outermost layer is dissolved and 
subsequently diffuses out of the delivery matrix. As the outermost layer gets depleted, the 
interface between the dissolution solution and the solid drug moves towards the core of the 
delivery system until the entire drug diffuses out of the delivery system 
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4.6 Mucoadhesive analysis- 
   
 
 
 
 
 
 
Figure 12. b-cGG sample adhered to the intestinal mucosa of goat 
The mucoadhesive study (figure 12) showed that the b-cGG sample was adhered to the 
intestinal mucosa for a period of 5 h. The result indicates that the developed products may be 
used successfully as a mucoadhesive delivery system. The vagina, which has a mucosal 
lining, may serve as an excellent biological substrate for the b-cGG and may be used 
successfully for delivering the drug into the vaginal lumen for a prolonged period. 
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5. Conclusion 
In the current study, successful attempts were made to develop biopolymeric suppositories 
for the treatment of BV. The formulations were tested under in vitro conditions on E. coli, 
taken as a model causative organism. The suppository were loaded with various bioactive 
agents (viz. lactic acid, metronidazole, ciprofloxacin and lactobacilli), either alone or in 
combination. Suppositories without any bioactive agents served as control. Ciprofloxacin 
containing suppositories showed to inhibit lactobacilli to a greater extent and were not found 
to be suitable for the treatment of BV. All other bioactive agents, when used alone or in 
combinations, showed beneficial effects to different extents and may be tried in the treatment 
of BV. The delivery system was found to be biodegradable in the presence of E. coli and may 
be used biodegradable delivery system. Suppository samples containing lactobacilli cells, 
except the sample containing a combination of lactic acid, metronidazole and lactobacilli, 
showed the growth of lactobacilli in the inhibition zone indicating their ability to recolonize 
the vaginal lumen. The release of metronidazole from the suppository indicated sustained 
delivery for a prolonged period and the release was found to be diffusion controlled. The 
suppository samples showed sufficient mucoadhesive property to be regarded as 
mucoadhesive delivery system. In short, the developed delivery systems may be used as a 
mucoadhesive delivery system for the delivery of bioactive agents in the vaginal lumen for 
the treatment of BV. 
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